Special Issue "Immune Checkpoint Inhibitor in Cancer Therapy: Recent Advances"
Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 7718
The treatment landscape for many cancers is rapidly evolving with the advent of immune checkpoint inhibitors and multi-omics. Combining the insights of next-generation sequencing along with transcriptomic and immunomic data can often inform treatment decision making for some cancers. In certain circumstances the use of immune checkpoint inhibitors has led to dramatic responses in various tumor types. Understanding which patients may yield the most benefit from these agents is of the utmost importance and interest of the greater oncology community. Deciphering how to hijack this response for patients who do not have such responses is also important and of interest. Various groups have led and continue to lead efforts into combining immune checkpoint in combination with various targeted therapies in efforts to improve responses to these agents. Additionally, there is an abundance of ongoing clinical trials to investigate novel checkpoints including but not limited to LAG-3, TIM3, TIGIT, and many more. Identifying which patients may have the most clinical benefit from these agents and how to predict which patients may have this benefit is part of the ongoing effort of the development of these agents. In this Special Issue, we aim to draw together research from experts in the field that highlight immunotherapeutic agents and strategies, and identify future directions that will lead to discoveries and therapies for these drugs in patients with cancer.
Dr. Jacob J Adashek
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- immune checkpoint inhibitor
- biomarker-driven trials
- precision medicine